The risk benefit ratio of glucocorticoids in SLE: have things changed over the past 40 years?
G StojanM Petri
Published in: Current treatment options in rheumatology (2017)
The use and dosing of glucocorticoids in SLE remains more art than science, although our knowledge regarding their complex genomic and non-genomic effects, as well as the resultant adverse effects, has greatly expanded over the past half a century.